FDA Approves New Influenza Vaccine Manufactured with Novel Technology - - BioPharm International

ADVERTISEMENT

FDA Approves New Influenza Vaccine Manufactured with Novel Technology



FDA has approved Protein Sciences’s FluBlok, a seasonal influenza vaccine made with novel technology. FluBlok uses recombinant DNA and a modified baculovirus (a virus that infects insects) to produce a safe and effective human influenza vaccine. FDA approved FluBlok for people 18–49 years old.

“This approval represents a technological advance in the manufacturing of an influenza vaccine,” said Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, in a Jan. 16, 2013, FDA press release. “The new technology offers the potential for faster start-up of the vaccine manufacturing process in the event of a pandemic because it is not dependent on an egg supply or on availability of the influenza virus.”

According to a press release, Flublok is an influenza vaccine made without the use of live influenza virus and it’s an egg-free influenza vaccine. In addition, it contains highly purified properties without preservatives (thimerosal), antibiotics, or adjuvants; and three times the active ingredient of that in traditional influenza vaccines.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here